Modality
mAb
MOA
Cl18.2
Target
AuroraA
Pathway
T-cell
MSHCC
Development Pipeline
Preclinical
~Oct 2019
→ ~Jan 2021
Phase 1
~Apr 2021
→ ~Jul 2022
Phase 2
~Oct 2022
→ ~Jan 2024
Phase 3
~Apr 2024
→ ~Jul 2025
NDA/BLA
Oct 2025
→ Jul 2030
NDA/BLACurrent
NCT05427972
670 pts·MS
2025-10→2030-07·Not yet recruiting
670 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-02-032mo agoPh1 Dose Esc· MS
2030-07-144.3y awayPh3 Readout· MS
Trial Timeline
Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
NDA/BLA
Not yet…
Catalysts
Ph1 Dose Esc
2026-02-03 · 2mo ago
MS
Ph3 Readout
2030-07-14 · 4.3y away
MS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05427972 | NDA/BLA | MS | Not yet recr... | 670 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Motarapivir | GSK | Preclinical | AuroraA | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| ARG-6988 | Argenx | Preclinical | AuroraA | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 | |
| Tiratapinarof | Intellia | NDA/BLA | APOC3 | |
| Semamavacamten | Ideaya Bio | Phase 1/2 | AuroraA |